This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
NGM Bio (NGM) Up on Fast Track Tag For Ophthalmology Drug
by Zacks Equity Research
The FDA bestows a Fast Track designation to NGM Bio's (NGM) product candidate, NGM621, for treating patients with geographic atrophy secondary to age-related macular degeneration. Stock up.
Apellis (APLS) Up More Than 40% in Past 3 Months: Here's Why
by Zacks Equity Research
Approval of Apellis' (APLS) Empaveli for treating paroxysmal nocturnal hemoglobinuria lends a significant boost to the company's growth prospects. The drug's label expansion studies also hold promise.
Apellis (APLS), Sobi Get EU Nod for Rare Blood Disorder Drug
by Zacks Equity Research
The European Commission approves Apellis (APLS) and Sobi's Aspaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients. Shares rise.
Apellis' (APLS) Q3 Loss Widens, Revenues Surpass Estimates
by Zacks Equity Research
Apellis (APLS) reports wider-than-expected loss for the third quarter of 2021 while revenues surpass expectations.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -31.79% and 143.22%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug (Revised)
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Apellis (APLS) Gets CHMP Nod for Rare Blood Disorder Drug
by Zacks Equity Research
The CHMP gives a positive opinion on and recommends granting marketing authorization to Apellis' (APLS) Aspaveli for the treatment of adults with paroxysmal nocturnal hemoglobinuria.
Apellis (APLS) Down on Mixed Data From Studies on GA Candidate
by Zacks Equity Research
Apellis (APLS) posts mixed top-line data from the phase III DERBY and OAKS studies testing pegcetacoplan in adults with geographic atrophy secondary to age-related macular degeneration. Stock falls.
Apellis Pharmaceuticals, Inc. (APLS) Down 6.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
AstraZeneca (AZN) Stops Phase III Study on Ultomiris for ALS
by Zacks Equity Research
AstraZeneca (AZN) stops the phase III CHAMPION-ALS study on Ultomiris for treating adults with amyotrophic lateral sclerosis, following a recommendation from the Independent Data Monitoring Committee.
Is the Options Market Predicting a Spike in Apellis (APLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.
Apellis' (APLS) Q2 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Apellis (APLS) reports a wider-than-expected loss for the second quarter of 2021. Revenues too miss expectations.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -60.00% and -72.43%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Why Apellis (APLS) Might Surprise This Earnings Season
by Zacks Equity Research
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Apellis (APLS) Up on Tie-up With Beam for Novel Therapies
by Zacks Equity Research
Apellis (APLS) signs a collaboration deal with Beam Therapeutics to develop new treatments for complement-driven diseases. Shares rise.
Apellis' (APLS) Empaveli Succeeds in Treatment-Naive PNH Study
by Zacks Equity Research
Apellis' (APLS) recently approved drug, Empaveli, demonstrates superiority in hemoglobin stabilization and reduction in LDH level in treatment-naive PNH patients.
Apellis (APLS) Gets a Boost With FDA Approval of PNH Drug
by Zacks Equity Research
Approval of Apellis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in the United States lends a significant boost to the company's growth prospects.
Is the Options Market Predicting a Spike in Apellis (APLS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Apellis (APLS) stock based on the movements in the options market lately.
Company News for May 18, 2021
by Zacks Equity Research
Companies In The News Are: HOME, MPC, UAL, APLS
Apellis' (APLS) Blood Disorder Drug Empaveli Gets FDA Nod
by Zacks Equity Research
The FDA approves Apeliis' (APLS) Empaveli for the treatment of paroxysmal nocturnal hemoglobinuria in adult patients.
Apellis' (APLS) Q1 Earnings Miss, Pegcetacoplan in Focus
by Zacks Equity Research
Apellis' (APLS) earnings lag estimates in the first quarter of 2021. Main focus of the company is on its lead pipeline candidate, pegcetacoplan.
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -37.28% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Apellis Pharmaceuticals, Inc. (APLS) Upgraded to Buy: Here's Why
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Apellis Pharmaceuticals, Inc. (APLS) Down 7.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.